Q3 FY26 results: revenue up 15%, adjusted PAT up 23.7%
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CORONA Remedies Q3 FY26 standalone revenue grew 15% YoY to Rs.342.42 Cr; nine-month revenue rose 16.3% to Rs.1,050.09 Cr. Reported Q3 PAT dipped to Rs.41.25 Cr from Rs.44.77 Cr due to a one-time Rs.19.10 Cr charge for new Labour Codes. Adjusted PAT grew 23.7% in Q3 and 30.7% for nine months. EBITDA margin: 24.3% in Q3, 22.0% for nine months. The company listed on NSE and BSE on Dec 15, 2025 via IPO. Deloitte issued an unqualified review.
Strong adjusted earnings growth supports story; one-time Labour Code charge drags reported Q3 PAT. Newly listed, watch execution.